Module 5: Clinical Outcomes by Disease Site - The use of proton therapy in the treatment of cancers of the head and neck


Secure Content

If you would like to request to license this or any other OncoLink content for your corporate or educational purposes, please contact our Director of Strategic Partnerships for pricing

Maggie Hampshire RN, BSN, OCN
Director of Strategic Partnerships
OncoLink
3400 Civic Center Boulevard, Suite 2338
Philadelphia, PA 19104

215-349-5445 (fax)
hampshire@uphs.upenn.edu


News
AACR: New Drug May Add to Therapy for Head and Neck CA

Sep 19, 2014 - The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association for Cancer Research's special conference "Targeting the PI3K-mTOR Network in Cancer," held from Sept. 14 to 17 in Philadelphia.



I Wish You Knew

Benefits of yoga during cancer treatment

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More